PGEN News & Analysis
2 articles
Market Mood
Precigen (PGEN) Announces Filing of Form 144 on August 3
Precigen (PGEN) has announced its filing of Form 144 on August 3. This form is typically used to notify the SEC of the sale of restricted or control securities. The filing indicates potential sales of company stock by insiders, which can affect market sentiment and trading volumes. This information is crucial for investors monitoring insider activities, as such transactions often signal management's confidence in the company's future performance.
Read More: Precigen (PGEN) Announces Filing of Form 144 on August 3
Precigen (PGEN) Share Trading at $4.02 with P/E Ratio of 9.14
Precigen, Inc. (PGEN) shares were trading at $4.02 as of April 28, with a forward P/E ratio of 9.14. The company recently transitioned to a commercial rare disease platform, following the approval of Papzimeous for recurrent respiratory papillomatosis. Market modeling predicts that by 2026, approximately 1,600–1,700 patients could be treated, rising to nearly 3,000 in 2027, which may lead to significant revenue fluctuations. Projections suggest potential quarterly earnings surprises exceeding 100% to 300% in 2026, setting the stage for notable market interest.
Read More: Precigen (PGEN) Share Trading at $4.02 with P/E Ratio of 9.14